Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy Designation

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Being Included in the List of Drugs Granted Breakthrough Therapy Designation

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment